Identification of new types of biomarkers and tracers for the in vivo molecular imaging of the pancreatic Beta-cell mass (KeyMarker)
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2011
- Initiating Organization: IBA Group
- Initiator Type: Industry
- Disease focus:
Type 2 Diabetes - Location: Europe
Abstract
Mission
The goal of KeyMarker is to identify molecules that can be used as radiotracers for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging and potential quantification of the pancreatic beta-cell mass. Such molecules may lead to novel approaches for diabetic disease management, such as patient stratification, disease follow-up, and therapeutic options. Several ligands for the target will be screened and evaluated through the preclinical models developed for the project. The in vitro/in vivo preclinical platform as well as the toxicology, bio-distribution, and labeling expertise dedicated to the project form the basis for a standard process for further diabetes imaging tracer evaluation.
Financing
This was a three-year project with a total budget of €2.7 million.
Links/Social Media Feed
Other website |
Points of Contact
Richard Zimmermann (project coordinator)
email: richard.zimmermann@iba-group.com
Sponsors & Partners
Eurogenetic |
FUNDP |
IBA |
Trasis |
UCL |
ULB |
ULg |